Relay Therapeutics Inc Total Liabilities
Relay Therapeutics Inc total liabilities. Based on the latest financial reports, Relay Therapeutics Inc (RLAY) has total liabilities worth $57.43 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See RLAY cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Relay Therapeutics Inc (2018–2025)
Total liabilities of Relay Therapeutics Inc from 2018 to 2025. This chart illustrates how Relay Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Relay Therapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Relay Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Relay Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Stadler Rail AG
SW:SRAIL
|
Switzerland | CHF5.35 Billion |
|
Agilysys Inc
NASDAQ:AGYS
|
USA | $134.52 Million |
|
Digitalbridge Group Inc
NYSE:DBRG
|
USA | $1.12 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥3.55 Billion |
|
First BanCorp
F:OLWN
|
Germany | €17.40 Billion |
|
ERMENEGILDO ZEG.DL -0001
F:JN0
|
Germany | €1.74 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr2.08 Billion |
|
China South Publishing & Media Group Co Ltd
SHG:601098
|
China | CN¥9.59 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Relay Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Relay Therapeutics Inc assets under control.
Liquidity & Leverage Metrics
Relay Therapeutics Inc Total Liabilities Ratios Explained
Relay Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 22.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Relay Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Relay Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Relay Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $54.27 Million | -41.96% |
| 2024-12-31 | $93.50 Million | +1.66% |
| 2023-12-31 | $91.98 Million | -38.50% |
| 2022-12-31 | $149.55 Million | +35.18% |
| 2021-12-31 | $110.64 Million | +202.81% |
| 2020-12-31 | $36.54 Million | -93.63% |
| 2019-12-31 | $573.51 Million | +6.30% |
| 2018-12-31 | $539.54 Million | -- |
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clin… Read more